Skip to main content

Table 3 Epigenetic agents as relapse therapy after haematopoietic transplantation (HSCT)

From: Epigenetic approaches in stem cell transplantation

Author

n

Agent

Disease

Remission

Outcome

Ref.

Giralt 1997

3

Dec

2× AML, 1× ALL

3× CR

1× relapse, 1× alive

(Giralt et al. 1997)

Ravandi 2001

14

Dec + HSCT

9× AML, 2× ALL, 3× CML

8× CR/PR

5× relapse, 5x alive

(Ravandi et al. 2001)

Jabbour 2009

9

5-Aza

AML

5× CR/PR

1× relapse, 7× alive

(Jabbour et al. 2009)

Czibere 2006

6

5-Aza + DLI

AML/MDS

3× CR, 2× PR

2× relapse, 2× alive

(Czibere et al. 2006)

  1. Decitabine (Dec) and 5-azacytidine (5-Aza) in combination with HSCT or donor lymphocyte infusion (DLI)
  2. AML acute myeloid leukaemia, MDS myelodysplasia, CML chronic myeloid leukaemia, ALL acute lymphoblastic leukaemia, CR complete remission, PR partial remission